JP2018506562A - ピロロピリジン化合物の結晶形態 - Google Patents

ピロロピリジン化合物の結晶形態 Download PDF

Info

Publication number
JP2018506562A
JP2018506562A JP2017545269A JP2017545269A JP2018506562A JP 2018506562 A JP2018506562 A JP 2018506562A JP 2017545269 A JP2017545269 A JP 2017545269A JP 2017545269 A JP2017545269 A JP 2017545269A JP 2018506562 A JP2018506562 A JP 2018506562A
Authority
JP
Japan
Prior art keywords
bromo
pyrrolo
aminopiperidin
pyridin
cyclopropanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017545269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506562A5 (cg-RX-API-DMAC10.html
Inventor
ジェフリー スタルツ,
ジェフリー スタルツ,
クリストファー エム. リンデマン,
クリストファー エム. リンデマン,
ケイス エル. スペンサー,
ケイス エル. スペンサー,
ウェイドン リウ,
ウェイドン リウ,
ジョセフ ルバック,
ジョセフ ルバック,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018506562(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2018506562A publication Critical patent/JP2018506562A/ja
Publication of JP2018506562A5 publication Critical patent/JP2018506562A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017545269A 2015-02-26 2016-02-26 ピロロピリジン化合物の結晶形態 Withdrawn JP2018506562A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (2)

Publication Number Publication Date
JP2018506562A true JP2018506562A (ja) 2018-03-08
JP2018506562A5 JP2018506562A5 (cg-RX-API-DMAC10.html) 2019-03-28

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545269A Withdrawn JP2018506562A (ja) 2015-02-26 2016-02-26 ピロロピリジン化合物の結晶形態

Country Status (21)

Country Link
US (2) US20160251350A1 (cg-RX-API-DMAC10.html)
EP (1) EP3262042A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018506562A (cg-RX-API-DMAC10.html)
KR (1) KR20170118762A (cg-RX-API-DMAC10.html)
CN (1) CN107406447A (cg-RX-API-DMAC10.html)
AR (1) AR103801A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016225070A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017018230A2 (cg-RX-API-DMAC10.html)
CA (1) CA2976665A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017002180A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017009662A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170439A (cg-RX-API-DMAC10.html)
HK (1) HK1246786A1 (cg-RX-API-DMAC10.html)
IL (1) IL254115A0 (cg-RX-API-DMAC10.html)
MA (1) MA41599A (cg-RX-API-DMAC10.html)
MX (1) MX2017010888A (cg-RX-API-DMAC10.html)
PE (1) PE20171327A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017501532A1 (cg-RX-API-DMAC10.html)
RU (1) RU2017133093A (cg-RX-API-DMAC10.html)
SG (1) SG11201706824TA (cg-RX-API-DMAC10.html)
WO (1) WO2016138458A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518906A (ja) * 2019-01-29 2022-03-17 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン塩

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518906A (ja) * 2019-01-29 2022-03-17 フヤ バイオサイエンス インターナショナル エルエルシー サルカルディン塩
JP2024039020A (ja) * 2019-01-29 2024-03-21 フヤバイオ インターナショナル,エルエルシー サルカルディン塩
JP2025165933A (ja) * 2019-01-29 2025-11-05 フヤバイオ インターナショナル,エルエルシー サルカルディン塩

Also Published As

Publication number Publication date
HK1246786A1 (zh) 2018-09-14
CN107406447A (zh) 2017-11-28
BR112017018230A2 (pt) 2018-04-17
CL2017002180A1 (es) 2018-03-16
IL254115A0 (en) 2017-10-31
KR20170118762A (ko) 2017-10-25
CR20170439A (es) 2018-01-08
PE20171327A1 (es) 2017-09-12
RU2017133093A (ru) 2019-03-26
EP3262042A1 (en) 2018-01-03
WO2016138458A1 (en) 2016-09-01
AU2016225070A1 (en) 2017-09-07
US20180282324A1 (en) 2018-10-04
US20160251350A1 (en) 2016-09-01
RU2017133093A3 (cg-RX-API-DMAC10.html) 2019-08-23
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
MA41599A (fr) 2018-01-02
CO2017009662A2 (es) 2018-02-28
MX2017010888A (es) 2017-12-15
SG11201706824TA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
JP7792942B2 (ja) テトラヒドロ-ピリド[3,4-b]インドールエストロゲン受容体モジュレーター及びその使用
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
EP3440067B1 (en) Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW202540122A (zh) Kras-g12d之氮雜-四環氧氮呯抑制劑的多晶型物及合成方法
EP2694072B2 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
US20190152970A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN114466839A (zh) Tead抑制剂和其用途
WO2017080966A1 (en) Tetrahydronaphthalene estrogen receptor modulators and uses thereof
JP2023530456A (ja) Cd73阻害剤の結晶形態及びその使用
CN111356456A (zh) 2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂
JP6851989B2 (ja) 医薬用共結晶及びその用途
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
US20180282324A1 (en) Crystalline forms of a pyrrolopyridine compound
CN110709079B (zh) 包含1,2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
HK40117290A (en) Pyrido[4,3-d]pyrimidine compounds
HK40091361A (en) Crystalline forms of a cd73 inhibitor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190218

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190924